Optima Cancer Protection

Optima Cancer Protection is the cancer-only, money-back, bank-channel CI policy for customers who want one risk addressed — cancer — at the lowest possible monthly ticket, with a meaningful guarantee that the premiums come back if nothing happens. It is a 10-year term policy distributed via Bank BCA, with three structural features that distinguish it from the broader critical-illness pack:

1. Two-stage cancer payout — 20% of Uang Pertanggungan (sum assured) on early-stage diagnosis, then the remaining 80% on late-stage progression. Most agency CI products pay the full sum on a single Major-CI trigger; this one separates them so the customer collects on both.
2. Premium waiver after the first early-stage claim — once the 20% benefit is paid, the customer stops paying premiums for the rest of the term and full late-stage cover stays alive.
3. No-claim bonus that returns 100% of premiums over the term — 30% of paid premiums refunded after Year 5 if no claim, 70% after Year 10 if no claim. Effectively a money-back wrapper around a cancer policy.

In one line: Pay a small monthly ticket for 10 years; if cancer hits early you get 20% up front and stop paying; if it never hits, you get every rupiah back.

The structural trade-off the agent must be honest about: the death benefit is return of premiums paid, not the headline sum assured. This is a cancer product, not a life product. The customer who treats it as life insurance will be disappointed at the first non-cancer death.

---

The RIPLAY illustration uses Dicky, 30yo male non-smoker, Plan 5, Rp 1 billion sum assured, Rp 900,000 monthly premium, 10-year payment term. Decoded:

Critical insight for the agent narrative: the no-claim bonus headline is the most common mis-selling trap on this product. 30% + 70% adds to 100% of each 5-year window’s premiums, not 100% of the full 10-year premium total. The RIPLAY math shows Rp 16.2M + Rp 37.8M = Rp 54M returned against Rp 108M paid — exactly 50%, not 100%. Customers who hear “premi kembali 100%” will feel cheated. Frame it correctly: half your premium comes back as cash if you stay claim-free; the other half is what you paid for 10 years of cancer protection — far cheaper than an equivalent multi-CI policy.

---

Sweet Spot — Lead with Optima Cancer Protection

• Age 28–45, married or with aging parents, BCA primary banking relationship
• Household income Rp 8M–25M/month — affordable mass-affluent, not HNW
• Family history of cancer — parents or siblings with cancer diagnosis, especially before age 60. This is the strongest single trigger for this product.
• Already has hospital reimbursement cover (BPJS Kesehatan or private medical) — this is the lump-sum cancer cash layer, not the hospitalisation layer
• Comfortable with monthly autodebet from BCA savings or BCA credit card; not interested in cash or transfer payments
• Wants a defined, finite commitment — 10 years and done, not a 30-year whole-life lock-in
• Risk-averse, money-back oriented — “kalau tidak kepakai, uang saya kembali” (if I don’t use it, my money comes back) resonates strongly

Borderline Fit — Discuss but qualify carefully

• Age 46–60 — still eligible (entry up to 60), but premium-to-SA ratio rises sharply; at age 55 the monthly premium for Rp 1B SA exceeds Rp 3M and the math stops competing with a multi-CI product like Prima Extra
• Customers who want comprehensive CI (heart attack, stroke, kidney failure, etc.) — Optima Cancer covers only cancer. They are the prospect for Prima Extra (AIA’s 136-condition lump-sum CI) or Allianz Critical+, not this product.
• Customers with USD income or USD obligations — this product is IDR-only; for cross-border families pair with an IDR cancer layer plus a separate USD legacy product
• Parents wanting to insure their child — entry age starts at 18, so this product does not apply for minors. Direct to AIA Nura Journey or PowerPro Life pediatric layers instead.

Do Not Pitch

• Anyone whose primary need is death benefit for dependants — the death benefit here is return of premiums, not sum assured. They are a term-life or whole-life prospect (AIA Melangkah Bersama, PowerPro Life, or LegacyPro on the Allianz side).
• Customers without basic hospital cover — sell them medical first; a cancer lump sum without hospital cashless coverage means they will still bleed cash on every chemo cycle and admission.
• Customers shopping because of a recent worrying symptom or family member’s recent diagnosis — the 90-day waiting period plus pre-existing exclusions create a real risk of a denied first claim and a complaint. Defer if you sense the buying trigger is acute.
• Customers without a BCA banking relationship who refuse to open one — payment must be BCA credit card or BCA savings autodebet. No other channel.
• Customers expecting health-insurance-style hospital reimbursement — wrong product. Optima Cancer pays a lump sum on diagnosis; it does not pay hospital bills directly.
• Heavy smokers in the 50+ bracket — premium loads are steep and the underwriting friction is high; the math rarely closes.

---

For Legacy Income agents this is mainly a comparison against AIA’s own Prima Extra (136-condition CI), Allianz Critical+ (multi-CI rider), and Pru Critical Benefit 88 (lump-sum CI to age 88). The honest question is: when is a cancer-only product the right answer instead of a multi-CI product?

Rule of thumb: if the customer’s first sentence contains “kanker” (cancer), “papa/mama kena kanker” (mum or dad got cancer), or “premi kembali” (premium back), Optima Cancer is in the conversation. If their first sentence contains “jantung” (heart), “stroke”, “warisan” (legacy), or “rumah sakit” (hospital), it is not.

---

Drawn from the category benchmarks JSON last revalidated 2026-05-19 — 26 catalogued CI products, 23 with PDFs extracted. Quantitative metrics across CI products meet none of the 60% coverage thresholds (premium tables, SA floors, condition counts, policy term — all below threshold). The benchmarking below is qualitative against the published category observations and structural comparison with the most-traded peers.

Confidence note: structural-dimension claims are drawn directly from the OCR’d RIPLAY (image-based PDF; OCR confidence high but residual error possible on tables). Premium economics are anchored on the single Dicky illustration; we do not have a brochure with full premium tables for other ages and SAs. Competitor comparison claims are analyst assessment from category knowledge, not directly benchmarked against parsed competitor RIPLAYs. Refresh trigger: re-run when CI category PDF coverage exceeds 60% and when a brochure with full premium grid becomes available.

---

Opening — establish the right frame

“Most of my clients tell me the same thing: their biggest fear isn’t dying, it’s getting cancer. The cost of treatment, the months out of work, the impact on the family. Let me show you a product designed for exactly that fear — and only that fear — so the price stays affordable.”

“Banyak nasabah saya bilang hal yang sama: ketakutan terbesar mereka bukan meninggal, tapi kena kanker. Biaya pengobatannya, berbulan-bulan tidak bisa kerja, dampaknya ke keluarga. Saya mau tunjukkan produk yang dirancang khusus untuk ketakutan itu — dan hanya itu — supaya harganya tetap terjangkau.”

The structural value prop (the “money-back cancer cover”)

“This policy works like this: you pay a small monthly premium for 10 years. If cancer is diagnosed early, you receive 20% of the sum assured right away — and you stop paying premiums for the rest of the term. If the cancer progresses to late stage, you receive the remaining 80%. And if nothing ever happens — which we all hope is the case — you get cashback in Year 5 and again in Year 10. About half of every rupiah you paid comes back to you.”

“Polis ini cara kerjanya begini: Anda bayar premi bulanan yang ringan selama 10 tahun. Kalau terdiagnosa kanker tahap awal, Anda terima 20% dari Uang Pertanggungan langsung — dan berhenti bayar premi sampai masa asuransi selesai. Kalau kankernya berkembang ke tahap akhir, Anda terima sisa 80%-nya. Dan kalau tidak terjadi apa-apa — yang tentu kita semua harapkan — Anda dapat cashback di Tahun ke-5 dan ke-10. Sekitar setengah dari setiap rupiah yang Anda bayar akan kembali.”

The honest framing (the cancer-only narrative)

“I want to be clear about one thing: this is a cancer policy, not a life policy. If you die from a heart attack tomorrow, your family gets back the premiums you paid — not the headline cover. That’s why we should think of this as one layer in your protection plan, not the whole plan. If you don’t have life cover yet, let’s talk about that next.”

“Saya mau jujur soal satu hal: ini polis kanker, bukan polis jiwa. Kalau Anda meninggal karena serangan jantung besok, keluarga Anda terima kembali premi yang sudah dibayar — bukan nilai pertanggungannya. Itu sebabnya kita harus melihat ini sebagai satu lapisan dalam rencana proteksi Anda, bukan keseluruhannya. Kalau Anda belum punya asuransi jiwa, mari kita bahas itu setelahnya.”

The family-history pitch (only when context fits)

“You mentioned your father was diagnosed with cancer at 58. That’s the strongest reason I would put this on the table for you. The genetic risk is real, the treatment cost is rising every year, and BPJS won’t fully cover an oncology bill. This is the cover that pays you cash on diagnosis — you decide how to spend it: best hospital, second opinion, time off work, anything.”

“Anda tadi cerita ayah Anda terdiagnosa kanker di usia 58. Itu alasan terkuat saya menawarkan produk ini. Risiko genetiknya nyata, biaya pengobatannya naik setiap tahun, dan BPJS tidak akan menutupi penuh tagihan onkologi. Ini perlindungan yang membayar Anda tunai begitu didiagnosa — Anda yang putuskan mau dipakai untuk apa: rumah sakit terbaik, second opinion, cuti kerja, apapun.”

The close — finite commitment, defined benefit

“You commit for 10 years, not for life. You know exactly what comes back if nothing happens. You know exactly what comes if cancer hits. There is no investment risk, no market exposure, no surprise. That kind of clarity is hard to find in insurance — and that’s why my clients with family history of cancer take this first, then add other layers afterwards.”

“Anda komit untuk 10 tahun, bukan seumur hidup. Anda tahu persis apa yang kembali kalau tidak terjadi apa-apa. Anda tahu persis apa yang Anda dapat kalau kanker terjadi. Tidak ada risiko investasi, tidak ada eksposur pasar, tidak ada kejutan. Kejelasan seperti itu jarang ditemukan dalam asuransi — itu sebabnya nasabah saya dengan riwayat keluarga kanker mengambil ini lebih dulu, baru menambah lapisan lain setelahnya.”

—

1. “Why only cancer? I want everything covered.”

Customer “Kenapa cuma kanker? Saya mau semua di-cover.”

Don't say “Cancer is the most common, so this is enough.” — overstates and creates a false-completeness impression.

Don't say “Kanker yang paling sering, jadi ini sudah cukup.”

Do say “You are right to ask. This product covers cancer only, by design. If you want heart, stroke, kidney, and the full critical-illness set in one policy, the right product is AIA Prima Extra or a multi-CI rider — and those cost more. The reason cancer-only products exist is that cancer is what most Indonesian families specifically worry about, and the focused design keeps the premium affordable. The honest play is often a combination: a multi-CI policy for breadth plus this one for extra cancer cover.”

Do say “Pertanyaan Anda tepat. Produk ini memang khusus kanker. Kalau Anda mau jantung, stroke, ginjal, dan semua penyakit kritis dalam satu polis, produk yang tepat adalah AIA Prima Extra atau rider multi-CI — dan harganya lebih tinggi. Alasan produk khusus kanker ini ada karena kanker memang ketakutan spesifik kebanyakan keluarga Indonesia, dan desain yang fokus membuat preminya terjangkau. Yang sering paling masuk akal justru kombinasi: polis multi-CI untuk cakupan luas plus produk ini sebagai tambahan khusus kanker.”

—

2. “Premi kembali 100%, kan? Berarti gratis dong?” / “Premiums come back 100%, so it is free?”

Customer “Premi kembali 100%, kan? Berarti gratis dong?”

Don't say “Yes, 100%.” — this is mis-selling. The RIPLAY math returns 50% of total premiums.

Don't say “Iya, 100%.”

Do say “Let me explain the math honestly. The bonus pays 30% of premiums paid in Years 1-5, then 70% of premiums paid in Years 6-10. Adding the rupiah amounts from the RIPLAY example: you pay Rp 108 million over 10 years; you get back Rp 54 million in bonuses. So roughly half comes back as cashback. The other half is what you paid for 10 years of cancer protection — which works out to about Rp 5.4 million per year for Rp 1 billion of cover. That is still cheap, but it is not zero. I want you to walk in with the right number.”

Do say “Saya jelaskan hitungannya dengan jujur. Bonus-nya membayar 30% dari premi yang Anda bayar di Tahun 1-5, lalu 70% dari premi yang Anda bayar di Tahun 6-10. Kalau saya jumlahkan angka rupiah dari contoh di RIPLAY: Anda bayar Rp 108 juta selama 10 tahun; Anda terima kembali Rp 54 juta dalam bentuk bonus. Jadi kira-kira separuh yang kembali sebagai cashback. Separuh lainnya adalah biaya Anda untuk 10 tahun perlindungan kanker — kira-kira Rp 5,4 juta per tahun untuk pertanggungan Rp 1 miliar. Itu tetap murah, tapi bukan nol. Saya mau Anda masuk dengan angka yang benar.”

—

3. “Kalau saya meninggal bukan karena kanker, gimana?” / “What if I die from something other than cancer?”

Customer “Kalau saya meninggal bukan karena kanker, gimana?”

Don't say “Your family still gets the sum assured.” — false, and a guaranteed complaint.

Don't say “Keluarga tetap dapat Uang Pertanggungannya.”

Do say “Honest answer: your family receives back the premiums you have paid, not the headline sum assured. That is by design — this is a cancer policy, not a life policy. That is exactly why I asked earlier whether you have life insurance separately. If not, the right move is to take a separate life policy alongside this — even a basic term-life is cheap. Optima Cancer is the cancer layer; the life policy is the life layer. They work together; one does not replace the other.”

Do say “Jawaban jujurnya: keluarga Anda menerima kembali premi yang sudah Anda bayar, bukan Uang Pertanggungannya. Itu memang desainnya — ini polis kanker, bukan polis jiwa. Itu sebabnya tadi saya tanya apakah Anda sudah punya asuransi jiwa terpisah. Kalau belum, langkah yang tepat adalah mengambil polis jiwa terpisah bersama ini — bahkan term-life dasar harganya murah. Optima Cancer adalah lapisan kanker; polis jiwanya adalah lapisan jiwa. Keduanya bekerja bersama; yang satu tidak menggantikan yang lain.”

—

4. “Saya sudah punya BPJS dan asuransi kesehatan dari kantor. Buat apa lagi?” / “I already have BPJS and a company health policy. Why this?”

Customer “Saya sudah punya BPJS dan asuransi kesehatan dari kantor. Buat apa lagi?”

Don't say “BPJS is not enough.” — too dismissive; the customer feels lectured.

Don't say “BPJS tidak cukup.”

Do say “BPJS and your company plan cover the hospital bill — admission, surgery, medication, the cashless side. What they do not cover well is the cancer journey beyond the hospital: months of recovery without work, second opinions, treatment in a non-network hospital, or the option to fly somewhere with better oncology. Optima Cancer pays you cash on diagnosis. You decide how to spend it. And company cover ends the day you leave the company — this one stays yours regardless of employment.”

Do say “BPJS dan polis kantor Anda menutupi tagihan rumah sakit — opname, operasi, obat, sisi cashless-nya. Yang tidak ter-cover dengan baik adalah perjalanan kanker di luar rumah sakit: berbulan-bulan pemulihan tanpa kerja, second opinion, pengobatan di rumah sakit non-jaringan, atau opsi terbang ke tempat dengan onkologi lebih baik. Optima Cancer membayar Anda tunai begitu didiagnosa. Anda yang putuskan mau dipakai untuk apa. Dan polis kantor berakhir di hari Anda berhenti kerja — yang ini tetap milik Anda, apapun status pekerjaan.”

—

5. “Bagaimana kalau saya didiagnosa segera setelah beli polis?” / “What if I get diagnosed right after I buy the policy?”

Customer “Bagaimana kalau saya didiagnosa segera setelah beli polis?”

Don't say “Don’t worry, you are covered.” — false; there is a 90-day waiting period.

Don't say “Tenang saja, sudah ter-cover.”

Do say “There is a 90-day waiting period from the policy start date. Any cancer where symptoms, signs, or diagnosis appeared during those first 90 days is not payable — that rule exists across the entire cancer-insurance category, not just AIA. There is also a 7-day survival period: you must survive 7 days after diagnosis for the claim to pay. I want to be transparent about both because if you have any current symptom you are worried about, this is the wrong moment to buy — we should defer until after you see a doctor and a diagnosis is either ruled out or known.”

Do say “Ada Masa Tunggu 90 hari sejak Tanggal Berlaku Polis. Kanker dengan gejala, tanda, atau diagnosa yang muncul dalam 90 hari pertama itu tidak dibayarkan — aturan ini berlaku di seluruh kategori asuransi kanker, bukan hanya AIA. Ada juga Masa Bertahan Hidup 7 hari: Anda harus bertahan hidup 7 hari setelah diagnosa supaya klaim dibayar. Saya mau transparan soal kedua hal ini karena kalau Anda saat ini punya gejala yang Anda khawatirkan, ini bukan waktu yang tepat untuk membeli — sebaiknya kita tunda dulu sampai Anda periksa ke dokter dan diagnosa entah dikesampingkan atau diketahui.”

—

These are the issues most likely to trigger an OJK complaint or churn-back from a customer in 2026 under the tightened conduct rules. Build agent training around avoiding all seven.

1. “Premi kembali 100%” overpromise. This is the single highest mis-selling risk on the product. The RIPLAY math returns Rp 54M out of Rp 108M paid — exactly 50%, not 100%. Every customer must be walked through the explicit rupiah math: total premium paid, total bonus payable, net cost of protection if no claim. Document the customer’s verbal understanding on the application record. The product literature uses “30% Tahap 1 + 70% Tahap 2” which sums visually to 100% — the agent’s job is to clarify that each tranche is of the 5-year window, not the full term.

2. Death benefit confusion. This product pays return of premiums on non-cancer death, not Uang Pertanggungan. Customers who interpret the headline Rp 1B as the death benefit will lodge a complaint at the first non-cancer death claim. Every SPAJ must include a separate disclosure that the customer understands the death benefit equals premiums paid plus waived premiums, not the headline cover.

3. POJK 36/2025 co-payment regime (effective Jan 2026). POJK 36/2025 imposes co-payment rules on health insurance products. Optima Cancer is classified as a health product (Asuransi Kesehatan in the RIPLAY) even though it pays cash, not reimbursement. Agents must clarify whether and how the co-payment regime applies to cancer lump-sum payouts — current AIA position should be confirmed in writing before any 2026 sale. Pending that confirmation, do not promise that the 20% / 80% payouts will be free of co-payment friction.

4. 90-day waiting period + 7-day survival. No cancer with symptoms, signs, or diagnosis arising during the first 90 calendar days from inception or reinstatement is payable. The customer must also survive 7 calendar days after diagnosis for the claim to trigger. Both rules must be walked through on application. If the customer has any current symptom they are worried about, defer the case — selling into a known undisclosed condition creates a future repudiation and a likely complaint.

5. Pre-existing exclusion is broad. The RIPLAY definition of Kondisi Yang Sudah Ada Sebelumnya (pre-existing conditions) covers any disease that has been examined, consulted, diagnosed, or treated before the policy effective date — even if not yet known to the customer in a confirmed way. Smokers, family-history customers, and anyone over 45 should be encouraged to do a baseline check-up before applying so any latent condition is either disclosed cleanly or ruled out before the policy starts.

6. BPJS adequacy claim. Do not pitch by undermining BPJS Kesehatan. The correct framing is “BPJS covers the hospital side; Optima Cancer pays you cash for everything else.” Saying “BPJS will not cover cancer” is factually wrong (BPJS does cover oncology to defined limits) and invites a regulator complaint.

7. RIPLAY-only data limitation — transparency point. This brief is reconstructed from the RIPLAY document alone; no brochure was available at the time of writing. The premium grid for ages and sums-assured other than the Dicky illustration is not in this analyst’s hands. Agents must produce a live quote in field for any prospect’s specific age, sex, and SA — never quote from this brief’s illustration as if it generalises across all ages and sums. Flag to ops if any brochure-driven feature emerges that contradicts this brief.

---

---

1. Build a one-page “True Cost of Cover” customer handout in EN + ID showing the explicit rupiah math: total premium paid, total bonus returned, net cost per year, what the policy pays in each scenario. This is the single highest-leverage mis-selling fix. Have every prospect sign it at SPAJ stage. Use the Dicky case as the worked example with a footer noting that the customer’s own quote will use their age, sex, and SA.

2. Build a “cancer layer + life layer” pair-sell deck. Every Optima Cancer pitch must be accompanied by the question: “Apakah Anda sudah punya asuransi jiwa?” (Do you already have life insurance?). If no, lead with AIA Melangkah Bersama, PowerPro Life, or LegacyPro first; Optima Cancer is the second layer. The pair-sell mindset will both raise case size and remove the structural mis-selling risk of a cancer-only product being sold as a life product.

3. Request the Lampiran Polis (condition annex) from AIA. The RIPLAY does not enumerate the early-stage and late-stage cancer condition lists — only the exclusions. For prospects with family histology concerns (specific cancer types, hereditary syndromes), the agent must be able to point to the exact list before the sale. Open a request now; expect 2-week turnaround.

4. Confirm POJK 36/2025 treatment in writing. AIA’s product team must confirm whether the January 2026 co-payment regime under POJK 36/2025 applies to Optima Cancer’s 20% / 80% cancer lump-sum payouts. The RIPLAY classifies the product as Asuransi Kesehatan (health insurance) which puts it inside the regime’s nominal scope, but a lump-sum diagnosis benefit may or may not be operationally affected. Get a written position before any 2026 sale and update talking points accordingly.

5. Refresh trigger. Re-run this brief when (a) the brochure with full premium grid becomes available, (b) CI category PDF coverage exceeds 60%, or © any policy-wording update post-1 January 2026 reflects co-payment changes. Until then, this brief stands as the primary internal reference and the underlying detailed product file at by-insurer/aia-indonesia/conventional/optima-cancer-protection.md should be updated from Path A (HTML-only) to Path B (RIPLAY parsed) using the OCR’d content captured during this brief.

---